Association between Copeptin and Metabolic Syndrome: A Systematic Review

Table 1

Characteristics of included studies assessing the relationship between copeptin and metabolic syndrome (n = 7).

Study id	Countries	Study designs	Sample sizes	Age (years) mean ± SD	Male sex (%)	Copeptin values (pmol/L) mean ± SD	MetS diagnostic criteria	% MetS	Quality score
Saleem-2009 (AA) [25]	USA	Cross-sectional	1293	63.6 ± 9.3	28.8	8.6 ± 5.7^a	ATP-III	50.4	9/10
Saleem-2009 (NHW) [25]	USA	Cross-sectional	1197	58.9 ± 10.2	42.6	5.4 ± 3.4^b	ATP-III	48.8	9/10
Enhörning-2011 [26]	Sweden	Cross-sectional	4742	57.5 ± 5.9	40.5	5.5 ± 3.7^b	ATP-III	21.5	8/10
Enhörning-2013 [27]	Sweden	Cohort	1653	NR	40.9	NR^b	ATP-III	26.2	9/9
Then-2015 (men) [28]	Germany	Cross-sectional	752	57.4 ± 13	100	10.3 ± 4.8^c	IDF	41.2	9/10
Then-2015 (women) [28]	Germany	Cross-sectional	788	56.2 ± 12.7	0	7.6 ± 4^c	IDF	25.0	9/10
Vintilă-2016 [29]	Romania	Case control	105	50.9 ± 1.4	21.9	NR^c	ATP-III	60.0	5/9
Canivell-2017 [30]	Switzerland	Cross-sectional	1089	47.4 ± 21.5	47	4.2 ± 2.4^c	ATP-III	13.4	8/10
Deligözoğlu-2020 [31]	Turkey	Cross-sectional	80	13.8 ± 1.93	44	30.2 ± 18.0^c	IDF	23.8	4/10

AA: African-Americans, NHW: non-Hispanic Whites, MetS: metabolic syndrome, ATP III: adult treatment panel III, IDF: international diabetes federation, SD: standard deviation, NR: not reported, ILMA: immunoluminometric assay, CLIA: chemiluminescence immunoassay, ELISA: enzyme-linked immunosorbent assay.